A vaccine given during pregnancy is significantly cutting hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials reporting a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by enhancing maternal immunity and transferring immunity through the placenta. A major new study analysing nearly 300,000 births across England between September 2024 and March 2025 has demonstrated the vaccine’s “excellent protection” during the period when infants are particularly susceptible to the virus. RSV affects roughly half of all newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the vaccine protects vulnerable infants
RSV, or respiratory syncytial virus, is a common respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild cold-like symptoms to causing severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the lung inflammation becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with bad infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is very, very frightening as a parent, frightening for good reason.”
The pregnancy vaccine works by activating the mother’s immune system to produce protective antibodies, which are then transferred to the foetus through the placenta. This maternal immunity provides newborns with immediate protection from the moment of birth, precisely when they are highly susceptible to RSV. The new study demonstrates that protection reaches approximately 85% when the vaccine is administered four weeks or more before delivery. Even shorter intervals between vaccination and birth can still provide meaningful protection, with evidence suggesting that a two-week gap is sufficient to shield babies born slightly early. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst noting that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent protection when vaccinated four weeks before birth
- Maternal antibodies passed through the placenta safeguard newborns from birth
- Coverage possible with two-week gap before premature birth
- Vaccination in the third trimester still offers meaningful infant protection
Compelling evidence from recent research
The performance of the RSV vaccine administered during pregnancy has been established through a comprehensive study conducted across England, analysing data from nearly 300,000 babies born between September 2024 and March 2025. This constitutes approximately 90 per cent of all births during that six-month period, providing strong and reliable data of the vaccine’s actual performance. The study’s conclusions have been validated by the UK Health Security Agency as showing robust protection for newborns during their most vulnerable early months. The scale of this research gives healthcare professionals and parents-to-be with confidence in the vaccine’s demonstrated effectiveness across varied populations and settings.
The results present a notable picture of the vaccine’s ability to protect. More than 4,500 babies were hospitalised with RSV throughout the study period, with the overwhelming majority being infants whose mothers had not received the vaccination. This clear distinction underscores the vaccine’s vital importance in reducing the risk of serious illness in newborns. The drop in hospital admissions surpassing 80 per cent represents a significant public health achievement, possibly preventing thousands of infants from experiencing the alarming and potentially severe symptoms connected with severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.
Research approach and coverage
The research examined birth and hospital admission records from England over a six-month timeframe, capturing data on approximately 90% of all births during this timeframe. By examining nearly 300,000 babies born to vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection levels and hospitalisations. The sizeable sample and comprehensive nature of the data collection ensured that findings were statistically robust and representative of the broader population, rather than isolated cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at differing periods before delivery. This allowed researchers to establish the minimum time required between vaccination and birth for maximum protection, as well as to determine whether protection continued to be effective with briefer timeframes. The methodology measured real-world outcomes rather than laboratory-based settings, providing tangible evidence of how the vaccine works when delivered across diverse clinical settings and patient circumstances throughout pregnancy’s final trimester.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Comprehending RSV and the risks
Respiratory syncytial virus, commonly referred to as RSV, is one of the leading causes of hospital admission in infants aged under twelve months across the United Kingdom. The virus affects roughly fifty per cent of all newborns during their first few months of life, with severity changing substantially from mild cold-like symptoms to severe, life-threatening chest infections. More than 20,000 babies require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on children’s wards and newborn care units during busier periods.
The infection causes deep inflammation in the lungs and airways, making it dangerously difficult for vulnerable newborns to feed and breathe adequately. Parents commonly see their babies fighting for breath, their chests rising whilst they try to pull adequate oxygen into their compromised lungs. Whilst the majority of babies improve through clinical support, a small but significant group succumb from RSV complications annually, making immunisation programmes a vital health service objective for safeguarding the most vulnerable and youngest people in our communities.
- RSV causes inflammation in lungs, causing severe breathing difficulties in babies
- Nearly 50% of infants contract the virus in their first few months of life
- Symptoms span from minor cold-like symptoms to life-threatening chest infections requiring hospitalisation
- Over 20,000 UK infants require serious hospital care for RSV annually
- Few babies succumb to RSV complications annually in the UK
Uptake rates and professional guidance
Since the RSV vaccine programme launched in 2024, health officials have emphasised the significance of pregnant women getting their jab at the ideal time for peak protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has emphasised that timing is crucial for guaranteeing newborns benefit from the strongest possible immunity from birth. Whilst the evidence indicates that vaccination at least four weeks before delivery offers approximately 85% protection, experts recommend women to receive their vaccine as early as possible from 28 weeks of pregnancy forward to enhance the antibodies transferred to their babies through the placenta.
The guidance from public health bodies remains clear: pregnant women should make a priority of getting vaccinated during their third trimester, even if circumstances mean they cannot get vaccinated at the best timing. Dr Watson has provided reassurance to pregnant women that protection remains still achievable with shorter intervals between vaccination and birth, including even a two-week gap for those delivering slightly early. This flexible approach acknowledges the realities of pregnancy and childbirth whilst maintaining strong protection for vulnerable newborns during their earliest and most vulnerable period when RSV represents the highest danger of severe infection.
Regional differences in vaccination
Whilst the RSV vaccine programme has been launched across England, uptake rates and deployment schedules have varied across different regions and NHS trusts. Some areas have attained higher vaccination coverage among eligible pregnant women, whilst others remain focused to boost understanding and availability of the jab. These geographical variations demonstrate differences across medical facilities, communication strategies, and community involvement initiatives, though the overall statistics shows consistently strong protection regardless of geographical location.
- NHS trusts deploying varied communication campaigns to engage with expectant mothers
- Inconsistencies across regions in immunisation take-up in different parts of England necessitate strategic intervention
- Regional health providers adapting programmes to suit specific population needs
Real-world impact and parent viewpoints
The vaccine’s outstanding effectiveness delivers concrete gains for families across the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV before the rollout of this preventative solution, the 80% reduction in admissions equates to thousands of infants protected against critical disease. Parents no longer face the troubling prospect of watching their newborns gasping for air or difficulty feeding, symptoms that characterise severe RSV infections. The vaccine has markedly changed the landscape of neonatal lung health, giving expectant mothers a preventative option to protect their most vulnerable children during those crucial first weeks.
For families like that of Malachi, whose acute RSV infection led to devastating brain damage, the vaccine’s accessibility carries deep personal significance. His mother’s promotion of the jab emphasises the profound consequences that preventable illness can inflict on young children and their families. Whilst Malachi’s experience precedes the vaccine programme, his story strikes a chord with parents now provided with protection. The knowledge that such grave complications—hospital admission, oxygen dependency, neurological damage—are now largely preventable has given considerable reassurance to women in pregnancy navigating their third trimester, changing what was once an predictable seasonal threat into a manageable health risk.